Clinical Trial Update: A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating non-inferior immunogenicity of Yuxi Walvax MPV ACYW vaccine in healthy children aged 2-10 years for meningococcal meningitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Meningitis

Drugs mentioned

• YW Walvax MPV ACYW vaccine (MPV ACYW vaccine)

Snippet

Sponsor: Walvax Biotechnology Co., Ltd. | Conditions: Neisseria Meningitides Meningitis | Phase 4 | Status: COMPLETED